These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 27363398)

  • 61. The effect of levodopa on respiration and word intelligibility in people with advanced Parkinson's disease.
    De Letter M; Santens P; De Bodt M; Van Maele G; Van Borsel J; Boon P
    Clin Neurol Neurosurg; 2007 Jul; 109(6):495-500. PubMed ID: 17509751
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease.
    Rodriguez-Oroz MC; López-Azcárate J; Garcia-Garcia D; Alegre M; Toledo J; Valencia M; Guridi J; Artieda J; Obeso JA
    Brain; 2011 Jan; 134(Pt 1):36-49. PubMed ID: 21059746
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Motor fluctuations in Parkinson's disease.
    Denny AP; Behari M
    J Neurol Sci; 1999 May; 165(1):18-23. PubMed ID: 10426141
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Acoustic analysis of parkinsonian speech I: speech characteristics and L-Dopa therapy.
    Goberman AM; Coelho C
    NeuroRehabilitation; 2002; 17(3):237-46. PubMed ID: 12237505
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Jaw movement dysfunction related to Parkinson's disease and partially modified by levodopa.
    Robertson LT; Hammerstad JP
    J Neurol Neurosurg Psychiatry; 1996 Jan; 60(1):41-50. PubMed ID: 8558149
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Therapeutic strategies to prevent motor complications in Parkinson's disease.
    Kieburtz K
    J Neurol; 2008 Aug; 255 Suppl 4():42-5. PubMed ID: 18821085
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Articulatory changes in muscle tension dysphonia: evidence of vowel space expansion following manual circumlaryngeal therapy.
    Roy N; Nissen SL; Dromey C; Sapir S
    J Commun Disord; 2009; 42(2):124-35. PubMed ID: 19054525
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ropinirole: a review of its use in the management of Parkinson's disease.
    Matheson AJ; Spencer CM
    Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Continuous dopaminergic stimulation, pulsatile dopaminergic stimulation].
    Destée A; Bordet R
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S69-82. PubMed ID: 12690666
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients.
    Simon N; Viallet F; Boulamery A; Eusebio A; Gayraud D; Azulay JP
    Eur J Clin Pharmacol; 2016 Apr; 72(4):423-30. PubMed ID: 26936272
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Rate of motor response to oral levodopa and the clinical progression of Parkinson's disease.
    Contin M; Riva R; Martinelli P; Triggs EJ; Albani F; Baruzzi A
    Neurology; 1996 Apr; 46(4):1055-8. PubMed ID: 8780090
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt MH; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Sep; 29(10):1273-80. PubMed ID: 25044402
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
    Nutt JG; Carter JH; Lea ES; Woodward WR
    Mov Disord; 1997 May; 12(3):285-92. PubMed ID: 9159720
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Levodopa and executive performance in Parkinson's disease: a randomized study.
    Pascual-Sedano B; Kulisevsky J; Barbanoj M; García-Sánchez C; Campolongo A; Gironell A; Pagonabarraga J; Gich I
    J Int Neuropsychol Soc; 2008 Sep; 14(5):832-41. PubMed ID: 18764978
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease.
    Kumar A; Mann S; Sossi V; Ruth TJ; Stoessl AJ; Schulzer M; Lee CS
    Brain; 2003 Dec; 126(Pt 12):2648-55. PubMed ID: 12937076
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Levodopa in the treatment of Parkinson's disease.
    Schapira AH; Emre M; Jenner P; Poewe W
    Eur J Neurol; 2009 Sep; 16(9):982-9. PubMed ID: 19538218
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Treatment of motor symptoms in Parkinson's disease].
    Morís-De la Tassa G; Arias-Rodríguez M
    Rev Neurol; 2009 Jan; 48 Suppl 1():S27-31. PubMed ID: 19222012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.